Biotech

Startups News

Biotech Startups Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Top news of the week: 19.04.2022.

Drug
Biotechnology
Finance
Hematology
Medicine
Bristol-Myers Squibb

Startups

@BentheFidler shared
On Apr 14, 2022
RT @LifeSciVC: Responding To Tough Markets: Restructurings In Biotech Observations on the flurry of #biotech restructurings, the different types of these announcements, and how to successfully navigate them Which will be the next Jazz, Arena, Illumina, or Madrigal? https://t.co/md3C2ePyW2
Open
Responding To Tough Markets: Restructurings In Biotech

Responding To Tough Markets: Restructurings In Biotech

Another day, another “restructuring” – there’s been a flurry of press releases recently using phrases like “exploring strategic alternatives”, “extending the cash runway”, and ...

@Forbes shared
On Apr 15, 2022
Several startup ecosystems, outside of Silicon Valley, have been quietly rising for more than 20 years. https://t.co/uyz2CG86GZ
Open
Location, Location, Location. Entrepreneurs, Where You Locate Your Startup Might Be As Important As The Timing

Location, Location, Location. Entrepreneurs, Where You Locate Your Startup Might Be As Important As The Timing

Several startup ecosystems, outside of Silicon Valley, have been quietly rising for more than 20 years.

@BentheFidler shared
On Apr 18, 2022
Troubling data leads a biotech to pull its prized drug from market and FDA review https://t.co/Amx3676Lek by @realJacobBell $TGTX - 23%
Open
Troubling data leads a biotech to pull its prized drug from market and FDA review

Troubling data leads a biotech to pull its prized drug from market and FDA review

Early analysis of a key clinical trial showed a potentially increased risk of death in cancer patients who received a combination treatment that included TG Therapeutics' approved medicine, ...

@BentheFidler shared
On Apr 18, 2022
Imara to reduce staff by 83% amid #biotech shakeout https://t.co/O6EHZHeAuc $IMRA
Open
Imara to reduce staff by 83% amid biotech shakeout

Imara to reduce staff by 83% amid biotech shakeout

The planned job cuts were announced days after Imara — one of three spinouts from the drug accelerator Cydan Development — stopped development of its top medicine.

@BentheFidler shared
On Apr 13, 2022
GSK acquires Sierra Oncology, betting $2B on a bone cancer drug with a long history https://t.co/ekNvr6lzwX Cytopia->YM Biosciences->Gilead->Sierra/ProNAI->GSK $SRRA $GSK $INCY $BMY $GILD
Open
GSK acquires Sierra Oncology, betting $2B on a bone cancer drug with a long history

GSK acquires Sierra Oncology, betting $2B on a bone cancer drug with a long history

The British pharma is buying into the potential of a medicine meant to treat the anemia often associated with myelofibrosis, a complication that isn't adequately addressed by current ...

@IAmBiotech shared
On Apr 14, 2022
Are you ready to partner at #BIO2022? Join us on April 21 at 10 AM PDT / 1 PM EDT for a candid chat w/ three major investors from the #biotech community. Gain valuable insights & be ready to ace pitching in the face of a down-trending market. https://t.co/5k84ZwjLX6 https://t.co/OuhEiFHcq9
Open
Pitching the Science of Tomorrow: How to Win in a Bear Market

Pitching the Science of Tomorrow: How to Win in a Bear Market

Join us on April 21st, 2022 @ 1pm ET for a candid chat with three major investors from our biotechnology community. Gain valuable insights and be ready to ace pitching world-changing ...

@NatureBiotech shared
On Apr 15, 2022
@medcitynews Ansa Biotechnologies raises $68 million in Series A funding #NBTintheNews via @pulse2news https://t.co/Z7tI0thZOB
Open
Ansa Biotechnologies Raises $68 Million In Series A Funding

Ansa Biotechnologies Raises $68 Million In Series A Funding

Ansa Biotechnologies recently announced it raised a $68 million round of funding. These are the details.

@WSJVC shared
On Apr 14, 2022
Alzheon’s Alzheimer’s drug is an oral tablet designed to prevent the formation of protein aggregates in the brain that damage neurons and their connections https://t.co/I8LCFqsvX4
Open
Alzheimer’s Drug Developer Alzheon Secures $50 Million

Alzheimer’s Drug Developer Alzheon Secures $50 Million

The Framingham, Mass.-based biotech company is testing the drug in late-stage, Phase 3 clinical trials.